Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 4
2004 2
2005 3
2006 1
2007 4
2008 4
2009 15
2010 12
2011 16
2012 19
2013 20
2014 15
2015 15
2016 19
2017 21
2018 15
2019 23
2020 26
2021 17
2022 13
2023 15
2024 34
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

290 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean huiqing wang (193 results)?
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators. Wang ML, et al. N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3. N Engl J Med. 2022. PMID: 35657079 Clinical Trial.
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Robak T, et al. Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348538 Clinical Trial.
New progress in HBV control and the cascade of health care for people living with HBV in China: evidence from the fourth national serological survey, 2020.
Hui Z, Yu W, Fuzhen W, Liping S, Guomin Z, Jianhua L, Feng W, Ning M, Jian L, Guowei D, Tongtong M, Lin T, Shuang Z, Mingshuang L, Yuan L, Xiaoqi W, Qianqian L, Qian Z, Dan W, Tingting Y, Qiudong S, Miao W, Li L, Qian H, Yixing L, Yi L, Shaodong Y, Zhijie A, Rodewald LE, Jidong J, Huaqing W, Wenzhou Y, Zhongfu L, Qun L, Zijian F, Zundong Y, Yu W. Hui Z, et al. Among authors: huaqing w. Lancet Reg Health West Pac. 2024 Sep 14;51:101193. doi: 10.1016/j.lanwpc.2024.101193. eCollection 2024 Oct. Lancet Reg Health West Pac. 2024. PMID: 39315090 Free PMC article.
A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study.
Chen M, Li L, Xia Q, Chen X, Liao Z, Wang C, Shen B, Zhou M, Zhang Q, Zhang Y, Qian L, Yuan X, Wang Z, Xue C, An X, Liu B, Gu K, Hou M, Wang X, Wang W, Li E, Zhong J, Cheng J, Shu Y, Yang N, Wang H, Yang R, Liu T, Deng T, Ma F, Liao W, Qiu W, Chen Y, Chen X, Zhang M, Xu R, Li X, Feng J, Ba Y, Shi Y. Chen M, et al. Among authors: wang h. Cancer. 2024 Apr 15;130(S8):1524-1538. doi: 10.1002/cncr.35292. Epub 2024 Mar 22. Cancer. 2024. PMID: 38515388 Free article.
CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma.
Zinzani PL, Wang H, Feng J, Kim TM, Tao R, Zhang H, Fogliatto L, Maluquer Artigal C, Özcan M, Yanez E, Kim WS, Kirtbaya D, Kriachok I, Maciel F, Xue H, Bouabdallah K, Phelps C, Chaturvedi S, Weispfenning A, Morcos PN, Odongo F, Buvaylo V, Childs BH, Dreyling M, Matasar M, Ghione P. Zinzani PL, et al. Among authors: wang h. Blood Adv. 2024 Sep 24;8(18):4866-4876. doi: 10.1182/bloodadvances.2024013236. Blood Adv. 2024. PMID: 39058951 Free PMC article. Clinical Trial.
290 results